0001144204-18-049515.txt : 20180914
0001144204-18-049515.hdr.sgml : 20180914
20180914163018
ACCESSION NUMBER: 0001144204-18-049515
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180913
FILED AS OF DATE: 20180914
DATE AS OF CHANGE: 20180914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shaaltiel Yoseph
CENTRAL INDEX KEY: 0001385118
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 181071468
MAIL ADDRESS:
STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC.
STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
BUSINESS PHONE: 972-4-988-9488
MAIL ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
tv502880_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-09-13
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001385118
Shaaltiel Yoseph
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT ST, SCIENCE PARK, POB 455
CARMIEL
L3
20100
ISRAEL
0
1
0
0
Executive VP, R&D
Stock Options (Right to Buy)
0.56
2018-09-13
4
A
0
700000
0
A
2028-09-13
Common Stock
700000
700000
D
The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.
/s/ Yossi Maimon, POA
2018-09-14